Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors

{{article.zuoZheEn}}

PDF(2461 KB)
PDF(2461 KB)
Front. Med. ›› 2022, Vol. 16 ›› Issue (5) : 773-783. DOI: 10.1007/s11684-021-0902-1
RESEARCH ARTICLE

Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors

  • {{article.zuoZheEn}}
Author information +
History +

Highlights

{{article.highlightEn}}

Abstract

{{article.abstractEn}}

Author summary

{{article.authorSummayEn}}

Keywords

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾
{{article.zuoZheEn_L}}. {{article.titleEn}}. Front. Med., 2022, 16(5): 773‒783 https://doi.org/10.1007/s11684-021-0902-1

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

RIGHTS & PERMISSIONS

{{article.copyright.year}} {{article.copyright.holder}}
PDF(2461 KB)

Accesses

Citations

Detail
Sections
Recommended

/

〈 〉